News
X T L Biopharmaceuticals
XTLB · TEL
$2.02+$0.05 (+2.54%)TodayMarket closed ·
Prev close $1.97
Latest news
- Press releaseGlobe Newswire
XTL Completed the Acquisition of Psyga Bio Ltd.
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Jumps 5%; Automatic Data Processing Posts Upbeat Earnings
- NewsAvi Kapoor
Dow Falls 100 Points; Brinker Earnings Beat Estimates
- Press releaseGlobe Newswire
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
- NewsLekha Gupta
Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments
- Press releaseGlobe Newswire
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
- Press releaseGlobe Newswire
XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
- NewsAvi Kapoor
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Why Vision Marine Technologies Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
X T L Biopharmaceuticals Earlier Announced Definitive Exclusive Sublicense Agreement With Biossil
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.